The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. | Pfizer...

While most of Gilead’s second-quarter presentation focused on its excitement over the launch of game-changing HIV PrEP drug Yeztugo, there was a disquieting sidebar as sales of its cell therapies w |...

Vor Bio has handed Dallan Murray a swift return to the workforce. | Vor Bio has handed Dallan Murray a swift return to the workforce. Weeks after being let go by Sarepta Therapeutics, Murray has...

As the Trump administration seeks to align U.S. | As the Trump administration seeks to align U.S. drug prices with lower reference costs in places like Europe, Eli Lilly’s CEO has cautioned that...

The FDA has removed a pause in the use of Valneva’s chikun | The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with stricter...

New Jersey biopharma CorMedix entered its commercial phase in 2023 with a long-awaited

Contract Development and Manufacturing Organizations (CDMOs) have carved out a lucrative niche within the biopharma industry, and the value of their collective capacity and production agility was o |...

After beating AstraZeneca’s Calquence in quarterly rev | After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa has pulled further...

When Bayer CEO Bill Anderson launched his Dynamic Shared Ownership (DSO) layoff plan—designed to save 2 billion euros ($2.3 billion) in 2026—he said it would be completed by the “end of 2025 at the |...

Novo Nordisk veteran Maziar Mike Doustdar—who is set to assume the role of CEO on Thursday—will have his work cut out turning things around at the Danish drugmaker, which is facing a commercial rec |...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for its GLP-1 diabetes and obesity drugs Ozempic and Wegovy, according to an |...

Thermo Fisher Scientific has implemented a string of layoffs in Carlsbad, California, in recent years, but it appears the company's cost-cutting drive is once again reaching the beachside city. |...

After Y-mAbs Therapeutics won its first FDA approval more than 4 years ago, the company has faced numerous hurdles on its quest to become an oncology powerhouse. | More than 4 years after its first...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into mult |...

Competition is coming for BioMarin’s potential blockbuster Voxzogo, but the California biotech may be able to answer with a longer-acting version of the C-type natriuretic peptide (CNP), which trea |...

President Donald Trump has doubled down on his plan to assess tariffs on importe | President Donald Trump has doubled down on his plan to assess tariffs on imported pharmaceutical products, saying...

As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing reform under the Trump administration, Pfizer CEO Albert Bourla, Ph.D.—w |...

As Eli Lilly rolls ahead with a $27 billion investment to prop up four new manufacturing facilities in the U.S, the company is moving to offload another plant with a checkered past. | As Eli Lilly...

While the JAK inhibitor market for alopecia areata (AA) has grown increasingly crowded in recent years, Rinvoq’s clinical performance in the hair follicle-attacking autoimmune disease could earn Ab |...

In his first public appearance as Incyte’s CEO, Bill Meury outlined his priorities for the company, which include taking a “fresh look” at the business' R&D, operating expenses and capital allo | In...